-
Most Recent
Search Results
240 results for BIOF
It’s the Right Price but the Wrong Time to Invest in iBio
With the underlying vaccination business, IBIO stock could make you rich. At the same time, if things go awry, it could make you poor in…
Why Investors Shouldn’t Bet on iBio Stock Now
There’s a much better way for investors to profit from a coronavirus vaccine than IBIO stock.
With iBio at 4-Week Lows, Now May Be the Time to Buy
IBIO stock is at a four-week low, so is now the time to invest in this biotech company searching for a Covid-19 vaccine?
There’s Little Reason to Hold Onto iBio Stock as it Chases Latest Virus
Traders have bought up a bunch of different biotech stocks as potential coronavirus cures. iBio is one that you should get rid of while it’s…
Get Out of IBIO Stock Before It’s Too Late
Since peaking at $7.45 per share in July, iBio’s stock price has fallen further from its 52-week high as hopes fade for the company to…
BITF Stock Alert: Bitfarms Names New CEO as Riot Pushes for a Takeover
Bitfarms stock is down on Tuesday as BITF investors react to the company naming a new CEO as it faces takeover from Riot Platforms.
Why Is Branchout Food (BOF) Stock Down 39% Today?
Branchout Food stock is down on Thursday after the company priced an offering of 1.75 million shares of BOF at 80 cents each.
We’ve Seen the iBio Stock Story Before — And It Doesn’t End Well
IBIO stock has soared on hopes for a coronavirus vaccine. But similar theses in the past have led to huge losses.
IBIO Stock may be a Hot Coronavirus Play, but Don’t Count on it Rising
IBIO stock is a hot coronavirus play, but don’t count on it rising. The equity line of credit deal it signed with Lincoln Park Capital…
Why iBio Is a Buy for Investors Thinking Past the Vaccine Race
An investment in IBIO stock is a bet on the company’s unique FastPharming system to create medications and therapies of all sorts.
Focus on iBio’s Tech, Not Its Coronavirus Story
IBIO stock shot up in March on news that it might produce a coronavirus vaccine. However, its at-scale production tech is more interesting.
For iBio, the Coronavirus Pandemic Was a Lucky Break
iBio’s production facility could be used to manufacture a Covid-19 vaccine. It remains to be seen if IBIO stock will be a star or a…
Bank of America Corp (BAC) Stock Still Has Plenty of Oomph
Bank of America’s strong run since last summer might appear to be at an end, but there are plenty of catalysts to drive BAC stock…
Turn Out the Lights on iBio’s Covid-19 Vaccine Party
IBIO stock is delivering heartache and more could be on the way as markets realize the company isn’t going to deliver a Covid-19 vaccine.
5 Best Stocks Under $5 This Week
A few biotech companies, such as Biocept and Cyclacel Pharmaceuticals, were among the best stocks below $5 this week.
BioVie (BIVI) Stock Pops on Positive Alzheimer’s Trial Results
The buying pressure is building with BIVI stock today as BioVie releases encouraging clinical trial results for a hard-to-treat ailment.
BMRN Stock Jumps 12% as Activist Elliott Targets BioMarin Pharmaceuticals
Shares of BMRN stock are on the move today as activist investor Elliott Investment Management builds a position in this drugmaker.
There Are Still Too Many Risks In iBio Stock
IBIO stock has retreated sharply in recent weeks, and looks more attractive on the dip. But even cheaper, the stock looks like an avoid.
Big Catalysts Are Just Around the Corner for iBio Stock
Asset prices don’t go up in a straight line, even if the company shows promise. Use the dip in IBIO stock now to get in…
It’s Time for Investors to Run Far Away From iBio Stock
Don’t let me talk you out of iBio stock, but a bit of skepticism is required given the massive hype behind this bio-pharmaceutical COVID-19 play.
iBio Is Losing Ground as the Covid-19 Vaccine Race Heats Up
iBio has had a thrilling 2020. But with its Covid-19 products far from approval, and others ahead, IBIO stock is set for a slump.
Small Patient Population? Charge $400K a Year for Your Drug
Companies like BioMarin Pharmaceutical are cashing in on rare diseases, where they can charge hundreds of thousands of dollars every year for their drugs.
iBio Will Survive Coronavirus Vaccine Disappointment, But It’s not a ‘Buy’
Investors pondering how a company with a history of moving back-and-forth between micro- and small-cap territory could adequately compete against more well-heeled rivals were right…
8 – 10 of 240 results
